We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.34 | 0.84% | 40.90 | 40.895 | 40.50 | 40.60 | 2,797,559 | 23:10:00 |
From Sep 2019 to Sep 2024
By Tapan Panchal
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that a phase III study to assess the efficacy of an investigational vaccine for the prevention of shingles has met its primary objective.
Analysis showed that the HZ/su vaccine reduced the risk of shingles by 97.2% in adults aged 50 years and older, compared with placebo.
Shingles is a type of rash that develops on one side of the human body caused by the chickenpox virus.
At 1209 GMT, shares of Glaxo were trading 0.5% higher at 1,354 pence.
-Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
